SFDA becomes first global regulator to approve Frehemgo for Hemophilia A bleeding prevention

RIYADH — The Saudi Food and Drug Authority (SFDA) has become the first regulatory body globally to approve the registration of Frehemgo (denecimig) for the routine prophylaxis of bleeding episodes in patients with hemophilia A, with or without factor VIII (FVIII) inhibitors. Hemophilia A is an inherited bleeding disorder caused by a deficiency or absence of FVIII, a protein essential for normal blood clotting, leaving patients at increased risk of recurrent bleeding. Before its approval, FREHEMG

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.